Brokerages Set Zura Bio Limited (NASDAQ:ZURA) PT at $15.80

Zura Bio Limited (NASDAQ:ZURA) has been assigned an average rating of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $15.80.

Several brokerages recently commented on ZURA. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Leerink Partners began coverage on shares of Zura Bio in a report on Monday, November 4th. They set an “outperform” rating and a $15.00 target price for the company. HC Wainwright restated a “neutral” rating and set a $5.00 target price on shares of Zura Bio in a report on Tuesday, December 24th. Chardan Capital reduced their target price on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 8th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th.

Insider Buying and Selling at Zura Bio

In other news, Director Parvinder Thiara sold 1,001,633 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $2.73, for a total value of $2,734,458.09. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 22.10% of the company’s stock.

Hedge Funds Weigh In On Zura Bio

Several large investors have recently modified their holdings of ZURA. JPMorgan Chase & Co. increased its position in Zura Bio by 12,060.8% during the fourth quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company’s stock worth $6,583,000 after acquiring an additional 2,611,532 shares during the period. Braidwell LP bought a new position in Zura Bio during the third quarter worth about $10,040,000. Geode Capital Management LLC increased its position in Zura Bio by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 955,426 shares of the company’s stock worth $2,389,000 after acquiring an additional 42,801 shares during the period. Sphera Funds Management LTD. bought a new position in Zura Bio during the third quarter worth about $2,999,000. Finally, Millennium Management LLC increased its position in Zura Bio by 1,499.0% during the fourth quarter. Millennium Management LLC now owns 701,278 shares of the company’s stock worth $1,753,000 after acquiring an additional 657,420 shares during the period. 61.14% of the stock is owned by institutional investors.

Zura Bio Trading Down 3.3 %

Zura Bio stock opened at $1.46 on Thursday. Zura Bio has a twelve month low of $1.35 and a twelve month high of $6.35. The company has a 50 day moving average of $2.00 and a 200-day moving average of $3.18.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.